pSivida launches social media push
11 April, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has launched channels on each of the four major social networks to provide more outlets to communicate key information to investors.
Tax reform story not over for biotech industry
11 April, 2013Building on the success of the Research and Development (R&D) Tax Incentive, industry leaders are calling for further tax reform to provide incentives for innovative manufacturing and investment, according to the Biotechnology Industry Position Survey 2013.
Australia’s first Biohackathon
09 April, 2013A Biohackathon will open up scientific problem solving to the public next week in Sydney.
Novogen reaches cancer drug milestone
09 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has revealed that one enantiomer of cancer drug candidate CS-6 appears many times more active against brain cancer than the reverse form.
Four more surgeons cleared to use CardioCel
09 April, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) says five surgeons have now received early approval to use heart patch CardioCel under the TGA’s Authorized Prescriber Scheme.
Beyond the debate
09 April, 2013 by Graeme O'NeillA leading opponent of transgenic crops in Britain recants. But Australian scientists developing GM crops to help feed the world aren’t waiting for local anti-GM campaigners to see the scientific light.
Clinuvel’s EU application for Scenesse delayed
09 April, 2013 by Dylan Bushell-EmblingThe EMA has allocated more time to review Clinuvel’s (ASX:CUV) application for approval of Scenesse as an EPP treatment.
McKeon Report echoes industry’s calls
09 April, 2013Amid the raft of federal government consultations and reviews in recent months - a record number of which impact biotechnology - the Strategic Review of Health and Medical Research in Australia has released its final report, echoing industry’s calls for commercialisation, clinical trials and IP support.
Company evaluating pSivida eye drug insert tech
08 April, 2013 by Dylan Bushell-EmblingA company is evaluating using pSivida’s (ASX:PVA) eye drug delivery technologies Durasert and Tethadur for its own ophthalmic drug products.
Phosphagenics gets ethics nod for pain patch trial
08 April, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has received ethics approval for a clinical trial of the redesigned version of pain patch TPM-oxycodone.
Alchemia granted oncology patent extension
05 April, 2013The US patent office has granted Alchemia (ASX:ACL) an extension for a key patent covering its HyACT oncology platform through to 2025.
Alchemia anticoagulant launches in India
04 April, 2013 by Dylan Bushell-EmblingAlchemia’s (ASX:ACL) marketing partner, Dr Reddy’s, has launched generic fondaparinux in India, marking its debut in a market outside of the US.
Novogen’s CS-6 cytotoxic to resistant cancer cells
04 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) shares surged on Wednesday after the company revealed lab results showing that its CS-6 candidate was highly cytotoxic to nigh-invulnerable ovarian cancer stem cell lines.
2013 Medical Device Commercialisation Seminar Series starts today
04 April, 2013The 2013 Medical Device Commercialisation Seminar Series explores what it takes to be one of the medical device success stories, helping today’s inventors fast-track to commercialisation.
$100 million allocated for new tranche of investment fund
04 April, 2013As part of the federal government’s recently announced industry and innovation plan ‘A Plan for Australian Jobs’, in which it announced a new $350 million round of the Innovation Investment Fund (IIF), $100 million has now been allocated.
